Clinical Trials Logo
  1. Home
  2. Tumors
  3. NCT01448759
  4. Details
NCT01448759 Clinical Trial

Evaluation of Plasma Alcohol Concentration in Patients Receiving Paclitaxel or Docetaxel

Tumors Clinical Trial

— ALCOOTAX  

Official title:
Prospective Evaluation of Plasma Alcohol Concentration in Patients Receiving Paclitaxel or Docetaxel Infusion

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01448759
Other study ID # IC 2011-03
Secondary ID
Status Completed
Phase N/A
First received October 6, 2011
Last updated April 23, 2015
Start date October 2011
Est. completion date February 2012

Study information
Verified date April 2015
Source Institut Curie
Contact n/a
Is FDA regulated No
Health authority France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate plasma alcohol concentration in patients receiving Paclitaxel or Docetaxel infusion.

Description:

In this study, there is no experimental treatment, or experimental care.

Recruitment information / eligibility
Status Completed
Enrollment 30
Est. completion date February 2012
Est. primary completion date February 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Chemotherapy with docetaxel or paclitaxel on an every 3-week schedule.

- Patient with bitherapy are eligible only if the taxane is the first infusion.

- All type of tumor.

- Age>18 years old.

- Signed written informed consent.

Exclusion Criteria:

- Patient under 18.

- Patient with bitherapy, if docetaxel or paclitaxel is not administered first.

- Patient deprived of liberty.

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label

Related Conditions & MeSH terms

Intervention

Other:
• blood sampling
Other: Blood sampling 10mL of peripherical blood will be collected specially for the study. It's an additional blood sampling compare to the normal follow up of the patient.

Locations
Country Name City State
France Institut Curie Paris

Sponsors (1)
Lead Sponsor Collaborator
Institut Curie

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary Evaluation of plasma alcohol Measure of the plasma alcohol level before and after a taxane-based therapy (docetaxel or paclitaxel) One year No
See also
  Status Clinical Trial Phase
Suspended NCT01562626 - Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors Phase 1/Phase 2
Completed NCT00435669 - A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664) Phase 1
Completed NCT00372437 - A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine Phase 1/Phase 2
Completed NCT00395434 - Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors Phase 1
Completed NCT00400023 - A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Solid Tumors Phase 1
Completed NCT00375245 - Rapamycin With Grapefruit Juice for Advanced Malignancies Phase 1
Completed NCT00410696 - Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy Phase 2
Recruiting NCT00553033 - Laparoscopic Liver Resection N/A
Completed NCT00248404 - NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS) Phase 1/Phase 2
Completed NCT00222443 - Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy Phase 1
Completed NCT00207103 - MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors Phase 1
Terminated NCT03251924 - A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05103969 - Cohort of Tumors With POLE/D1 Mutation
Completed NCT00446446 - PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer) Phase 2
Completed NCT02275910 - Phase 1 Study of E7090 in Subjects With Solid Tumor Phase 1
Terminated NCT02271516 - to evaluate188Re-BMEDA-liposome in Patient With Primary Solid Tumor in Advanced or Metastatic Stage Phase 1
Terminated NCT01081808 - Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors Phase 1
Completed NCT00389480 - Study of AR-67 (Formerly DB-67) in Adult Patients With Refractory or Metastatic Solid Malignancies Phase 1
Completed NCT00398814 - Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers Phase 1
Terminated NCT00130936 - Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates Phase 1/Phase 2